Shire announced the launch of Cuvitru (immune globulin subcutaneous [human], 20% solution) indicated as replacement therapy for primary humoral immunodeficiency (PI) in patients aged ≥2 years. Shire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results